We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Vertex Pharmaceuticals Incorporated
74 own
47 watching
Current Price
$308.54
$3.67
(1.2%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
79,185.48M
52-Week High
325.19
52-Week Low
225.28
Average Volume
1.3M
Dividend Yield
--
P/E Ratio
23.0149
Market Capitalization79,185.48M52-Week High325.1952-Week Low225.28Average Volume1.3MDividend Yield--P/E Ratio23.0149What does the Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More
How much money does Vertex Pharmaceuticals Incorporated make?
News & Events about Vertex Pharmaceuticals Incorporated.
Ticker Report
6days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX Get Rating) Director Lloyd Carney sold 2,700 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $320.52, for a total value of $865,404.00. Following the transaction, the ...
Ticker Report
9days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX Get Rating) Director Yuchun Lee sold 4,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, January 25th. The stock was sold at an average price of $313.96, for a total transaction of $1,255,840.00. Following the ...
PR Newswire
21days ago
Thinking about trading options or stock in Tesla, STMicroelectronics, ASML Holding, Vertex Pharmaceuticals, or Exxon Mobil? Thinking about trading options or stock in Tesla, STMicroelectronics, ASML Holding, Vertex Pharmaceuticals, or Exxon Mobil? PR Newswire NEW YORK, Jan. 18, 2023 NEW YORK, Jan...
Business Wire
1month ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT. A live webcast of management's remarks will be available through the Vertex website...
Zolmax
1month ago
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX Get Rating) have been given a consensus recommendation of Moderate Buy by the twenty-two research firms that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating, ten have given a buy ...
Frequently Asked Questions
Frequently Asked Questions
What is Vertex Pharmaceuticals Incorporated share price today?
Can Indians buy Vertex Pharmaceuticals Incorporated shares?
How can I buy Vertex Pharmaceuticals Incorporated shares from India?
Can Fractional shares of Vertex Pharmaceuticals Incorporated be purchased?
What are the documents required to start investing in Vertex Pharmaceuticals Incorporated stocks?
What is today’s traded volume of Vertex Pharmaceuticals Incorporated?
What is today’s market capitalisation of Vertex Pharmaceuticals Incorporated?
What is the 52-Week High and Low Range of Vertex Pharmaceuticals Incorporated?
What percentage is Vertex Pharmaceuticals Incorporated down from its 52-Week High?
What percentage is Vertex Pharmaceuticals Incorporated up from its 52-Week Low?
Current Price
$308.54
$3.67
(1.2%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.